Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 8, 2019


bluebird bio, Inc.

(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)




60 Binney Street,

Cambridge, MA  



(Address of Principal Executive Offices)


(Zip Code)

Registrant’s Telephone Number, Including Area Code: (339) 499-9300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 8.01Other Events.


On January 8, 2019, bluebird bio, Inc. conducted an investor presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.  A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 9.01Financial Statements and Exhibits.

(d) Exhibits











Investor presentation provided by bluebird bio, Inc. on January 8, 2019.




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.







Date: January 8, 2019

bluebird bio, Inc.





/s/ Jason F. Cole




Jason F. Cole




Chief Legal Officer






Slide 1

READY TO RECODE 37th Annual J.P. Morgan Healthcare Conference January 8, 2019 NASDAQ: BLUE Exhibit 99.1

Slide 2

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding the initiation, timing, progress and results of our preclinical and clinical studies and our research and development programs, our ability to advance product candidates into, and successfully complete, clinical studies, and the timing or likelihood of regulatory filings and approvals are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties that are described in our most recent quarterly report on Form 10-Q, as well as our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Forward-Looking Statements

Slide 3

RADICAL CARE We care in a way that’s intense and truly sets us apart. WE RECODE FOR LIFE THIS IS PERSONAL Gene therapy is about saving lives one person at a time. And we are, each of us, personally all in. PIONEERS WITH PURPOSE We’re exploring new frontiers for the sake of patients.

Slide 4

We LIVE By Our Non-negotiables

Slide 5

T H E G E N E T H E R A P Y P R O D U C T S C O M P A N Y LentiGlobin SCD 2022 Potential Filing/Approval LentiGlobin TDT 2019 EU Potential Approval 2020 U.S. Potential Approval Lenti-D CALD 2020 Potential Approval bb2121 Multiple Myeloma 2020 Potential Approval Products on the Market 4 INDs per year starting in 2020 1-2 Clinical Programs 5+ Patient Impact ∞ Our 2022 Vision -- Just Got BOLDER Products on the Market

Slide 6

SCD: Potential Global LAUNCH MM: Earlier Line APPROVALS & LAUNCHES 2023+ SCD: U.S. & EU FILING/APPROVALS MM: Earlier Line Studies 2022 TDT: Label EXPANSION CALD: Global EXPANSION MM: Global EXPANSION in Relapsed/Refractory Earlier Line Studies 2021 TDT: EU Country EXPANSION U.S. APPROVAL & LAUNCH Label EXPANSION CALD: U.S./EU APPROVAL MM: APPROVAL in Relapsed/Refractory 2020 TDT: EU APPROVAL & 1st LAUNCH 2019 UNPRECEDENTED OPPORTUNITY Anticipated research, development, regulatory and commercial milestones 1-2 INDs 1-2 INDs 1-2 INDs 1-2 Clinical Starts 5+ New Clinical Programs

Slide 7


Slide 8

RECODE THE SCIENCE: R&D with SOUL WHAT YOU SEE WHAT YOU DON’T SEE Internal Research Tools & Technology P13K Inhibition Enhanced Mftg TGF-B Flip CBL-B Edit DARIC Controls GAMMA DELTA Partners for Success T Cell megaTALs PRODUCT CANDIDATES PROGRAM AREA PRECLINICAL PHASE 1/2 PHASE 2/3 RIGHTS/PARTNER Severe Genetic Diseases Lenti-D™ Drug Product Worldwide LentiGlobin™ Drug Product Worldwide BCL11a shRNA (miR)* Worldwide Cancer bb2121 Celgene bb21217 Celgene Multiple Myeloma Third Line** Cerebral Adrenoleukodystrophy Transfusion-Dependent β-Thalassemia β0/β0 Multiple Myeloma Fourth Line Sickle Cell Disease Multiple Myeloma First Line** Multiple Myeloma Second Line** *Development is led by Dana-Farber/Boston Children's Cancer and Blood Disorders Center **Planned studies ** Multiple Myeloma Fourth Line Transfusion-Dependent β-Thalassemia Non-β0/β0 Sickle Cell Disease

Slide 9

Anti-Pure Play Principles - What Do We Mean? RECODING TRADITIONAL R&D 1:Many Target Strategy INTEGRATE ITERATE INTERNAL EXTERNAL Platform Tools & Technology R&D Enablers Clinical Insights MM - bb21217 SCD - BCL11a Liquid Tumor Programs Solid Tumor Programs SGD Programs TDT – LentiGlobin SCD – LentiGlobin MM – bb2121 CALD – Lenti-D

Slide 10

Our Philosophy Applied in a Tumor Microenvironment

Slide 11

Oncology Pipeline Enabled by Our Partners and Our Core Technologies Two Academic Clinical Trial Starts Planned in 2019 20+ 2+ 15+

Slide 12

Research Strategy Yielding Emerging Oncology Pipeline PRECLINICAL DEVELOPMENT EARLY CLINICAL LATE CLINICAL TARGET VALIDATION 2020 & BEYOND: 1-2 INDs PER YEAR bb21217 MM bb2121 MM LentiGlobin TDT LentiGlobin SCD Lenti-D CALD BCL11A SCD Dual-targeted CAR Liquid tumor Next gen + megaTAL edit Binders, Potency Internal Program Medigene Collaboration TCR target Solid tumors Next gen + Synbio Potency TCR target (viral antigen) Solid tumors Next gen + megaTAL edit Potency Fred Hutch Collaboration Clinic Ready 2019 CAR target Solid tumor Next gen + Synbio Target, Binders, Potency Regeneron Collaboration CAR target Solid tumors Next gen + Synbio Binders & Potency UNC Collaboration Clinic Ready 2019

Slide 13


Slide 14

RECODE THE SYSTEMS: ANYTHING BUT TRADITIONAL UNKNOWN IMPACT ONE-TIME POTENTIALLY CURATIVE OUR GOAL - MAKE IT SEAMLESS TO ALL STAKEHOLDERS Novel Science/Medicine Vector Production Bold & Balanced Access Model Supply Chain & Patient Management Drug Product Production

Slide 15

Virus Manufacturing Drug Product SCALABLE Clinical Data Real World Evidence to Support BLUE Style: Field Team Supply Chain Collecting Cells, Preparing, Shipping, Receiving Cells DELIVERY PLATFOM Platform Is Gearing Up for Launch TDT MAKE IT SEAMLESS

Slide 16

Preparing to Serve Patients in Europe in 2019 Apheresis Coordinator Apheresis Operator Cell Lab Operator Transplant Coordinator Transplant Nurse Transplant Physician Transplant Administrator bbb Manufacturing Logistics Apheresis Personnel Cell Lab Personnel Transplant Personnel (ATC) Manufacturer Launch Expectations: Optimal patient experience through a seamless delivery network Steady country by country launch with progressive build Get the model right for long term success Advance value-based payment over time reimbursement *Will support future launches in 2020+ 3 - Germany 4 - Italy 2 - UK 4 - France (in 2020)* 1 Drug Product Manufacturing Munich, Germany 9 Qualified Treatment Centers at 2019 Launch &

Slide 17


Slide 18

Business of Cures – Complex with Lots of Questions, Perspectives, etc. Price? Revenue? Value? Affordability? Cost Effectiveness? COGs? Value-based Payments? Price Increases? One-Time? “Gene therapy could be cost effective in SMA, but not at $4M” “How much would you pay for the miracle of gene therapy?”  “Can Pay-For-Results Drug Pricing Work?” “Value-Based Pricing And Reimbursement: Still More Promise Than Reality”  

Slide 19

bluebird Access Strategy – Proactive and Transparent Approach January 8, 2019 “Biotech Proposes Paying for Pricey Drugs by Installment”

Slide 20

Access and Reimbursement Model – A Major Opportunity Across Stakeholders Focus is on difficulties and barriers, NOT solutions Growing alignment on value & outcome based payment models The Will To Recode One-Time Treatment Potentially Curative Product Engine Unconstrained BLUEBIRD OPPORTUNITY System NOT setup for one-time potentially curative treatments Focus is on price, NOT on value

Slide 21

Keep It Simple, Keep It Focused on the Patient & the Long Term BLUE VALUE PRINCIPLES Focus on patient innovation and access  Creative and disruptive Flexible and share risk  Transparent, proud and proactive Don’t do silly short sighted stuff Don’t truncate value because it’s a one-time potentially curative treatment Don’t price at what you can get away with or what the market can bear Focus on real value delivered to the patient & system Unapologetically fund & reward innovation that matters &

Slide 22

Our Goal Is to Simultaneously Achieve Five Key Objectives BLUE has CONVICTION in the VALUE of the LIFELONG transformative benefit that our therapies may bring to patients, physicians, caregivers, healthcare systems and society at large 1 BLUE is willing to SHARE the RISK of uncertainty to PROVE the life long value of its therapies 2 BLUE wants to be a CATALYST for CHANGE to establish a SUSTAINABLE MODEL for pricing & reimbursement of gene therapies 5 BLUE wants to make its treatments AFFORDABLE so PATIENTS (and SYSTEM) can actually REALIZE the VALUE of its therapies 3 4

Slide 23

Lifetime cost-time effectiveness timeframe Base value only on patient QOL and Life Extension OBJECTIVE STRATEGIC APPROACH Approach – VALUE-BASED PAYMENT Over Time Based on OUTCOME FAIR VALUE RECOGNITION SHARED RISK HEALTH SYSTEM AFFORDABILITY PER PATIENT AFFORDABILITY Pay ONLY IF the treatment works Put UP TO 80% of the price at risk based on success Spread payments over UP TO A FIVE YEAR period NO PRICE INCREASES above CPI NO COST after payment period (vs. for life) 1 2 3 4

Slide 24

TRADITIONAL FOR LIFE MODEL* Lifetime (50 years) $300 -$600k $300 -$600k $300 -$600k $300 -$600k $300 -$600k $300 -$600k $300 -$600k $300 -$600k $300 -$600k $300 - $600k 1 2 3 4 5 6 7 8 9 10 $1.5M - $3M $3M - $5M $13M - $29.5M POTENTIAL BLUEBIRD APPROACH NO COST X X X X X Only with Success 1 2 3 4 5 No price increase beyond CPI Years Years Payment Model – Patient and System Friendly Treatment Costs Over Time *Ranges based on 2018 U.S. list prices from a sampling of seven chronic rare disease therapies.

Slide 25

Payment Model – Sharing Risk & Value with the System POTENTIAL BLUE APPROACH NO COST X X X X X Only with Success 1 2 3 4 5 No price increase beyond CPI Years Spread payments over UP TO FIVE years UP TO 80% of payment only made upon treatment success No payments after payment period Proactively commit to NO PRICE INCREASES over CPI

Slide 26

Not the Easy Path but the Challenges Are Solvable POTENTIAL BLUE APPROACH NO COST X X X X X Only with Success 1 2 3 4 5 No price increase beyond CPI Years Spread payments over UP TO FIVE Years UP TO 80% of payment only made upon treatment success No payments after payment period Proactively commit to NO PRICE INCREASES over CPI TRACKABILITY? Challenge: What happens when patient changes payer? Possible Solutions: Address in contract negotiation, mutual recognition strategy across payers, etc. PORTABILITY? BEST PRICE? Challenge: How do you define and track outcomes? Possible Solutions: Payer to use claims and/or registry data Challenge: How do you handle Medicaid “Best Price” rules? Possible Solutions: Innovative federal or state pilot programs or waivers

Slide 27

Lifetime cost-time effectiveness timeframe Base value only on patient QOL and Life Extension OBJECTIVE STRATEGIC APPROACH VALUE-BASED PAYMENT Over Time Based on OUTCOMES FAIR VALUE RECOGNITION 1 What is the value that LentiGlobin can bring to TDT patients, payers, system and society? AND how can it be fairly measured?

Slide 28

LentiGlobin, if successful, has the potential to relieve patients of their daily disease and treatment-related burden, and patients may live a longer life Impact of One-Time Potentially Curative Treatment? LIFE EXTENSION COST OF CARE REDUCTIONS QUALITY OF LIFE IMPROVEMENTS SOCIETAL BENEFITS What Value Can LentiGlobin Bring to TDT Patients, Payers and System? Disease and treatment-related burden builds up over time and can even lead to early death Pain Fatigue Time Lost due to Transfusion Inability to Work Iron Overload Cost & Time for Care Cost of Chelation Tethered to Healthcare System Impact on the Blood Supply Organ Failure Depression

Slide 29

Cost Effective Analysis Focused on Actual Patient Value: QOL and Life Extension *We have quantified the impact on patient quality of life, survival, treatment cost and society using established modeling techniques Quality of Life $4M $3M $2M $1M $0 Societal Value Life Extension Traditional All Inclusive Calculation Cost Offsets (U.S./EU Vary) (Returned To The System) Quality of Life $2M $1M $0 LentiGlobin Intrinsic Value Life Extension $2.1M The actual LentiGlobin price is TBD, but will not exceed the intrinsic value (total value minus cost offsets). THE VALUE AT WHICH TREATMENT IS COST EFFECTIVE* (NOT PRICE) Clinical Trial Data Outcomes Research Real World Evidence Economic Modeling QUALITY OF LIFE IMPROVEMENTS LIFE EXTENSION COST OF CARE REDUCTIONS SOCIETAL BENEFITS

Slide 30

Catalyst for Change - Recode the Status Quo for the Better Value-based payment over time tied to outcomes Base value only on actual patient value (no offsets) Payments over ~5 years with up to 80% at risk No price increases beyond CPI Actual price TBD, but will not exceed intrinsic value CATALYST FOR CHANGE 5

Slide 31

Our ambition is to recode science, systems and the status quo, so lives can be lived fully. WE RECODE FOR LIFE